Skip to content

News

Aptamer Group and Bio-Works Technologies partner to enable improved solutions for gene therapy manufacturing Aptamer Group and ProAxsis Limited enter partnership to improve global logistics and stability of diagnostic tests Aptamer Group signs large commercial agreement with a public life science research company Aptamer Group and WuXi AppTec Research Service Division collaborate to identify new Optimer™ enabled therapeutics Aptamer Group partners with top five global pharmaceutical company to support innovative vaccine development Aptamer Group appoints Jordan Clark as Chief Commercial Officer Aptamer Group and PinotBio collaborate to develop new therapeutic drug conjugates Aptamer Group collaborates with world-leading pharmaceutical company to evaluate Optimer technology Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test Aptamer Group extends collaboration with leading biopharmaceutical company to explore next-generation drug delivery approaches New COO appointed at Aptamer Group Aptamer Group makes progress in 2020 Aptamer Group advances COVID-19 testing capabilities with Integumen MP praises Aptamer Group’s COVID-19 work Aptamer Group attracts top talent to its scientific team Aptamer Group and Cytiva form new collaboration for the development of COVID-19 Rapid Test Aptamer Group CTO tells LBC radio about new rapid COVID-19 test Integumen signs MTA with Aptamer Group Ltd Aptamer Group making headlines on their Point of Care COVID-19 reagent developments Aptamer Group and Valitacell announce partnership to build new drug discovery platform Aptamer Therapeutics and Cancer Research UK announce partnership for drug development programme Aptamer Group Announces Agreement with AstraZeneca to Explore Next-Generation Drug Delivery Devices Expansion plans to support Aptamer Group growth Aptamer Group Secures $2.2m Series A Investment

Start your next project with Aptamer Group

Contact one of our experts today